DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells

References

• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26:s33–s50.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14:2047–2058.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.
   PubMed Web of Science ®Google Scholar
• Paneni F, Lüscher TF. Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Cardiol. 2017;120:S17–S27.
   PubMed Web of Science ®Google Scholar
• Cutshall BT, Twilla JD, Olinger AS, et al. A review on cardiovascular effects of newer hypoglycaemic medications. Ann Med. 2017;49:603–612.
   PubMed Web of Science ®Google Scholar
• Xie W, Song X, Liu Z. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascul Pharmacol. 2018;109:17–26.
   PubMed Web of Science ®Google Scholar
• Kato N, Oka M, Murase T, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem. 2011;19:7221–7227.
   PubMed Web of Science ®Google Scholar
• Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013;154:1260–1270.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu X, Liu Y, et al. The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury. Mol Med Rep. 2017;16:8003–8010.
   PubMed Web of Science ®Google Scholar
• Ikedo T, Minami M, Kataoka H, et al. Dipeptidyl peptidase-4 inhibitor anagliptin prevents intracranial aneurysm growth by suppressing macrophage infiltration and activation. J Am Heart Assoc. 2017;6:e004777.
   PubMed Web of Science ®Google Scholar
• Sato A, Suzuki S, Watanabe S, et al. DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction. Int Heart J. 2017;58:778–786.
   PubMed Web of Science ®Google Scholar
• Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015;8:163–171.
   PubMed Web of Science ®Google Scholar
• Chiba Y, Yamakawa T, Tsuchiya H, et al. Effect of anagliptin on glycemic and lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res. 2018;10:648–656.
   PubMedGoogle Scholar
• Faria RX, Gonzaga DTG, Pacheco PAF, et al. Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells. J Bioenerg Biomembr. 2018;50:81–91.
   PubMed Web of Science ®Google Scholar
• Piskozub M, Króliczewska B, Króliczewski J. Ribosome nascent chain complexes of the chloroplast-encoded cytochrome b6 thylakoid membrane protein interact with cpSRP54 but not with cpSecY. J Bioenerg Biomembr. 2015;47:265–278.
   PubMed Web of Science ®Google Scholar
• Hosseinimehr SJ, Safavi Z, Kangarani Farahani S, et al. The synergistic effect of mefenamic acid with ionizing radiation in colon cancer. J Bioenerg Biomembr. 2019;51:249–257.
   PubMed Web of Science ®Google Scholar
• Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500–508.
   PubMed Web of Science ®Google Scholar
• Kuznetsov AV, Javadov S, Sickinger S, et al. H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation. Biochim Biophys Acta. 2015;1853:276–284.
   PubMed Web of Science ®Google Scholar
• Zhou S, Sun W, Zhang Z, et al. The role of Nrf2-mediated pathway in cardiac remodeling and heart failure. Oxid Med Cell Longev. 2014;2014:260429.
   PubMed Web of Science ®Google Scholar
• Otterbein LE, Foresti R, Motterlini R. Heme oxygenase-1 and carbon monoxide in the heart: the balancing act between danger signaling and pro-survival. Circ Res. 2016;118:1940–1959.
   PubMed Web of Science ®Google Scholar
• Czibik G, Derumeaux G, Sawaki D, et al. Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology. Basic Res Cardiol. 2014;109:450.
   PubMed Web of Science ®Google Scholar
• Chen H, Jiang Z. The essential adaptors of innate immune signaling. Protein Cell. 2013;4:27–39.
   PubMed Web of Science ®Google Scholar
• Liang J, Li L, Sun Y, et al. The protective effect of activating Nrf2/HO-1 signaling pathway on cardiomyocyte apoptosis after coronary microembolization in rats. BMC Cardiovasc Disord. 2017;17:272.
   PubMed Web of Science ®Google Scholar
• Faridvand Y, Nozari S, Vahedian V, et al. Nrf2 activation and down-regulation of HMGB1 and MyD88 expression by amnion membrane extracts in response to the hypoxia-induced injury in cardiac H9c2 cells. Biomed Pharmacother. 2019;109:360–368.
   PubMed Web of Science ®Google Scholar
• Jiang T, Jiang D, Zhang L, et al. Anagliptin ameliorates high glucose-induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1. Mol Immunol. 2019;107:54–60.
   PubMed Web of Science ®Google Scholar
• Li Q, Li J, Liu Y, et al. Anagliptin prevents apoptosis of human umbilical vein endothelial cells by modulating NOX-4 signaling pathways. Biomed Pharmacother. 2018;103:1623–1631.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang M, Xuan L, et al. Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall. Free Radic Biol Med. 2018;121:105–116.
   PubMed Web of Science ®Google Scholar
• Sato H, Kubota N, Kubota T, et al. Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. Diabetologia. 2016;59:2426–2434.
   PubMed Web of Science ®Google Scholar
• Ueda S, Shimabukuro M, Arasaki O, et al. Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk: rationale and study design of the reason trial. Cardiovasc Drugs Ther. 2018;32:73–80.
   PubMed Web of Science ®Google Scholar